The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TLX | -60.78% | N/A | N/A | -53% |
| S&P | +15.58% | +78.13% | +12.24% | +17% |
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
No news articles found for Telix Pharmaceuticals.
| Q1 2024 | YOY Change | |
|---|---|---|
| Revenue | $115.04M | 0.0% |
| Gross Profit | $75.94M | 0.0% |
| Gross Margin | 66.01% | 0.0% |
| Net Income | $11.82M | 0.0% |
| EBITDA | $21.26M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q1 2024 | YOY Change | |
|---|---|---|
| Net Cash | $80.05M | 0.0% |
| Accounts Receivable | $54.23M | 0.0% |
| Inventory | 12.5 | 0.0% |
| Q1 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $11.07M | 0.0% |
| Short Term Debt | $1.38M | 0.0% |
No data available for this period.
| Q1 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | $2.03M | 0.0% |
| Operating Free Cash Flow | $3.60M | 0.0% |
| Metric | Q1 2024 | YoY Change |
|---|---|---|
| Total Debt | $12.45M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
